Sciwind In-licenses Sanofi's Portfolio of GIP Agonists for Obesity and Diabetes

Hangzhou Sciwind Biosciences in-licensed global rights to Sanofi's portfolio of long-lasting glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. Sciwind is a clinical-stage biopharma that is developing three GLP-1 receptor agonist candidates for NASH and other metabolic conditions. Its technologies include oral peptide and inhaled protein therapeutics delivery. Sciwind plans to test Sanofi's candidates in combination with its own molecules. Financial details of the agreement were not disclosed. More details.... Share this with colleagues: // //